Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

网站地图 | English | 公务邮箱

About the library

Background
History
Leadership
Organization

Opening Hours
Collections
Help Via Email

Electronic Information Resources

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

详细信息查看全文

作者：Michael P. Smith¹ ; ⁶ ; Holly Brunton¹ ; ⁶ ; Emily J. Rowling¹ ; Jennifer Ferguson¹ ; Imanol Arozarena¹ ; Zsofia Miskolczi¹ ; Jessica L. Lee¹ ; Maria R. Girotti² ; Richard Marais² ; Mitchell P. Levesque³ ; Reinhard Dummer³ ; Dennie T. Frederick⁴ ; Keith T. Flaherty⁴ ; Zachary A. Cooper⁵ ; Jennifer A. Wargo⁵ ; Claudia Wellbrock¹ ; ^{claudia.wellbrock@manchester.ac.uk" class="auth_mail" title="E-mail the corresponding author}
刊名：Cancer Cell
出版年：2016
出版时间：14 March 2016
年：2016
卷：29
期：3
页码：270-284
全文大小：5115 K

文摘

•: MITF is a driver of a reversible non-mutational drug-tolerance phase in melanoma
•: Drug repositioning identifies nelfinavir mesylate as a suppressor of MITF expression
•: Nelfinavir sensitizes BRAF and NRAS mutant melanoma to MAPK inhibitor treatment
•: A nelfinavir combination therapy overcomes NRAS-driven acquired resistance

NGLC 2004-2010.National Geological Library of China All Rights Reserved.
Add:29 Xueyuan Rd,Haidian District,Beijing,PRC. Mail Add: 8324 mailbox 100083
For exchange or info please contact us via email.